GlassScriptPhysician profile
Jonathan B Rudick
NPI 1124083704
$7,161.13
in general payments reported to CMS, 2019-2025
30 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $258 · 2021: $506 · 2022: $1,044 · 2023: $1,390 · 2024: $1,664 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,452 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,451.96 |
| Education | $116.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,133.99 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $664.38 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $494.13 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $447.66 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $444.86 | 2019-2025 | Veltassa |
| Amgen INC. | $419.87 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Travere Therapeutics, INC. | $344.34 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $300.94 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $288.43 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Mallinckrodt Enterprises LLC | $281.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.97 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $231.13 | 2019-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $214.70 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $206.64 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $193.93 | 2024-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $192.79 | 2022-2024 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $168.47 | 2019-2023 | Krystexxa |
| Alnylam Pharmaceuticals INC. | $141.40 | 2020-2025 | Givlaari |
| Ani Pharmaceuticals, INC. | $135.46 | 2022 | |
| Akebia Therapeutics INC | $131.36 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $72.86 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $72.13 | 2021-2023 | Gattex |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.93 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $66.46 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $44.05 | 2024 | Crysvita |
| Kyowa Kirin, INC. | $41.97 | 2023-2025 | Crysvita |
| Recor Medical INC | $25.25 | 2025 | Paradise Ultrasound Renal Denervation System |
| Shield Therapeutics INC | $21.95 | 2023 | Accrufer |
| Shire North American Group INC | $17.67 | 2019 | |
| Genzyme Corporation | $17.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rudick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.